Related references
Note: Only part of the references are listed.The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models
Alessandro De Vita et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas
Alessandro De Vita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
Jane Thomas et al.
CLINICAL COLORECTAL CANCER (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype
Javier Martin-Broto et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
Dominga Racanelli et al.
FRONTIERS IN ONCOLOGY (2020)
The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements
Albert J. Suurmeijer et al.
GENES CHROMOSOMES & CANCER (2019)
Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions
Cristina R. Antonescu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
New fusion sarcomas: histopathology and clinical significance of selected entities
Markku Miettinen et al.
HUMAN PATHOLOGY (2019)
Infantile NTRK-associated Mesenchymal Tumors
Jessica L. Davis et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2018)
Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion
Yosef Landman et al.
CLINICAL BREAST CANCER (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma
Hadeel Halalsheh et al.
PEDIATRIC BLOOD & CANCER (2018)
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Alessandro De Vita et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2018)
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
David S. Ziegler et al.
BRITISH JOURNAL OF CANCER (2018)
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents
Alessandro De Vita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Management and potentialities of primary cancer cultures in preclinical and translational studies
Giacomo Miserocchi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Myxofibrosarcoma primary cultures: molecular and pharmacological profile
Alessandro De Vita et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors
Narasimhan P. Agaram et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern
Florian Haller et al.
JOURNAL OF PATHOLOGY (2016)
Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
Alessandro De Vita et al.
MOLECULES (2016)
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101
Ramamoorthy Nagasubramanian et al.
PEDIATRIC BLOOD & CANCER (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini et al.
MOLECULAR ONCOLOGY (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
TrkB inhibition as a therapeutic target for CNS-related disorders
Fabien Boulle et al.
PROGRESS IN NEUROBIOLOGY (2012)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability
C. Miquel et al.
ONCOGENE (2007)
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
C Tognon et al.
CANCER CELL (2002)
Share Paper
